Use of transient elastography (FibroScan®) for the noninvasive assessment of portal hypertension in HIV/HCV-coinfected patients

被引:47
作者
Sanchez-Conde, M. [1 ]
Miralles, P. [1 ]
Maria Bellon, J. [2 ]
Rincon, D. [3 ]
Ramirez, M. [1 ]
Gutierrez, I. [1 ]
Ripoll, C. [3 ]
Lopez, J. C. [1 ]
Cosin, J. [1 ]
Clemente, G. [3 ]
Lo Iacono, O. [3 ]
Banares, R. [3 ,4 ]
Berenguer, J. [1 ]
机构
[1] Hosp Gen Univ Gregorio Maranon, Infect Dis & HIV Unit, Madrid, Spain
[2] Hosp Gen Univ Gregorio Maranon, Biomed Res Fdn, Madrid, Spain
[3] Hosp Gen Univ Gregorio Maranon, Hepatol Unit, Madrid, Spain
[4] Spanish CIBERehd Res Grp, Barcelona, Spain
关键词
hepatitis C infection; HIV infection; liver cirrhosis; liver pathology; HUMAN-IMMUNODEFICIENCY-VIRUS; HEPATITIS-C VIRUS; VENOUS-PRESSURE GRADIENT; STAGE LIVER-DISEASE; INFECTED PATIENTS; THERAPEUTIC STRATEGIES; NATURAL-HISTORY; FIBROSIS; CIRRHOSIS; PROGRESSION;
D O I
10.1111/j.1365-2893.2010.01371.x
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
The hepatic venous pressure gradient (HVPG) is the gold standard for assessing portal pressure and correlates with the occurrence of portal hypertension (PH)-related complications. Transient elastography (TE) is a new, highly accurate noninvasive technique, which enables us to evaluate hepatic fibrosis to detect advanced fibrosis and cirrhosis. We performed a hepatic haemodynamic study and TE in 38 HIV/HCV-coinfected patients. The association between HVPG and liver stiffness was assessed by linear regression. The diagnostic value of TE was assessed by receiver operating characteristic (ROC) curves. We considered clinically significant PH as an HVPG >= 10 mmHg and severe PH as an HVPG 12 mmHg. A total of 38 HIV/HCV-coinfected patients were included. Twenty-eight patients (73.7%) had clinically significant PH (HVPG >= 10 mmHg), and 23 (60.5%) of these had severe PH (HVPG >= 12 mmHg). We found a statistically significant association between liver stiffness (kPa) and HVPG(r(2) = 0.46, P < 0.001, straight line equation HVPG = 7.4 + 0.204*TE). The areas under the ROC curves were 0.80 [95% confidence interval (CI), 0.64-0.97] and 0.80 (95% CI, 0.66-0.94) for the prediction of HVPG 10 and 12 mmHg, respectively. Our data suggest that TE can predict the presence of clinically significant and severe PH in HIV/HCV-coinfected patients.
引用
收藏
页码:685 / 691
页数:7
相关论文
共 50 条
  • [41] Prognostic value of liver stiffness in HIV/HCV-Coinfected patients with decompensated cirrhosis
    Leire Pérez-Latorre
    Matilde Sánchez-Conde
    Pilar Miralles
    Juan Carlos López
    Francisco Parras
    Francisco Tejerina
    Teresa Aldámiz-Echevarría
    Ana Carrero
    Cristina Díez
    Margarita Ramírez
    Isabel Gutiérrez
    José María Bellón
    Rafael Bañares
    Juan Berenguer
    BMC Infectious Diseases, 18
  • [42] Association of adiponectin (ADIPOQ) rs2241766 polymorphism and dyslipidemia in HIV/HCV-coinfected patients
    Pineda-Tenor, Daniel
    Berenguer, Juan
    Garcia-Broncano, Pilar
    Jimenez-Sousa, Maria A.
    Fernandez-Rodriguez, Amanda
    Diez, Cristina
    Garcia-Alvarez, Monica
    Carrero, Ana
    Catalan, Pilar
    Aldamiz-Echevarria, Teresa
    Resino, Salvador
    EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, 2014, 44 (05) : 453 - 462
  • [43] Transient elastography: A non-invasive tool for assessing liver fibrosis in HIV/HCV patients
    Vecchi, Valentina Li
    Soresi, Maurizio
    Colomba, Claudia
    Mazzola, Giovanni
    Colletti, Pietro
    Mineo, Maurizio
    Di Carlo, Paola
    La Spada, Emanuele
    Vizzini, Giovanni
    Montalto, Giuseppe
    WORLD JOURNAL OF GASTROENTEROLOGY, 2010, 16 (41) : 5225 - 5232
  • [44] Transmission networks of hepatitis C virus among HIV/HCV-coinfected patients in Guangdong, China
    Deng, Xizi
    Liang, Zhiwei
    Cai, Weiping
    Li, Feng
    Li, Junbin
    Hu, Fengyu
    Lan, Yun
    VIROLOGY JOURNAL, 2022, 19 (01)
  • [45] PBMCs gene expression predicts liver fibrosis regression after successful HCV therapy in HIV/HCV-coinfected patients
    Virseda-Berdices, Ana
    Brochado-Kith, Oscar
    Berenguer, Juan
    Gonzalez-Garcia, Juan
    Perez-Latorre, Leire
    Busca, Carmen
    Diez, Cristina
    Mican, Rafael
    Fernandez-Rodriguez, Amanda
    Jimenez-Sousa, Maria angeles
    Resino, Salvador
    FRONTIERS IN PHARMACOLOGY, 2025, 15
  • [46] Hepatitis C virus (HCV) treatment uptake and changes in the prevalence of HCV genotypes in HIV/HCV-coinfected patients
    Medrano, J.
    Resino, S.
    Vispo, E.
    Madejon, A.
    Labarga, P.
    Tuma, P.
    Martin-Carbonero, L.
    Barreiro, P.
    Rodriguez-Novoa, S.
    Jimenez-Nacher, I.
    Soriano, V.
    JOURNAL OF VIRAL HEPATITIS, 2011, 18 (05) : 325 - 330
  • [47] Comparison of transient elastography (FibroScan), FibroTest, APRI and two algorithms combining these non-invasive tests for liver fibrosis staging in HIV/HCV coinfected patients: ANRS CO13 HEPAVIH and FIBROSTIC collaboration
    Castera, L.
    Winnock, M.
    Pambrun, E.
    Paradis, V.
    Perez, P.
    Loko, M-A
    Asselineau, J.
    Dabis, F.
    Degos, F.
    Salmon, D.
    HIV MEDICINE, 2014, 15 (01) : 30 - 39
  • [48] Effect of mono/dual antiretroviral therapy on suppression of HCV and HIV during treatment of HCV infection in HIV/HCV-coinfected patients
    Martin-Carbonero, Luz
    Dominguez-Dominguez, Lourdes
    Bailon, Lucia
    Torres, Rafael
    Rubio, Rafael
    Ron, Raquel
    Moreno, Francisco
    Rico, Mikel
    Jimenez-Nacher, Inmaculada
    Gonzalez-Garcia, Juan
    Pulido, Federico
    Luisa Montes, Maria
    ENFERMEDADES INFECCIOSAS Y MICROBIOLOGIA CLINICA, 2019, 37 (06): : 367 - 372
  • [49] Assessment of liver fibrosis by transient elastography (Fibroscan®) in patients with A1AT deficiency
    Guillaud, Olivier
    Dumortier, Jerome
    Traclet, Julie
    Restier, Lioara
    Joly, Philippe
    Chapuis-Cellier, Colette
    Lachaux, Alain
    Mornex, Jean Francois
    CLINICS AND RESEARCH IN HEPATOLOGY AND GASTROENTEROLOGY, 2019, 43 (01) : 77 - 81
  • [50] Persistently normal alanine aminotransferase levels in HIV/HCV-coinfected patients: the role of steatosis
    Bani-Sadr, F.
    Barange, K.
    Daoud, F.
    Jacomet, C.
    Bicart-See, A.
    Rosenthal, E.
    Cacoub, P.
    Pol, S.
    Perronne, C.
    Carrat, F.
    HIV MEDICINE, 2009, 10 (07) : 417 - 421